Revolution Medicines (RVMD) Set to Post Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) will likely be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Revolution Medicines to post earnings of ($2.35) per share and revenue of $25.58 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter last year, the company earned ($1.31) earnings per share. On average, analysts expect Revolution Medicines to post ($8.94) EPS for the current fiscal year and ($6.29) EPS for the next fiscal year.

Revolution Medicines Trading Up 1.3%

RVMD stock opened at $186.22 on Wednesday. Revolution Medicines has a fifty-two week low of $56.66 and a fifty-two week high of $224.31. The business’s 50 day moving average price is $200.66 and its two-hundred day moving average price is $154.67.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wolfe Research restated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a research note on Monday, August 10th. Sanford C. Bernstein upped their price target on Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research note on Friday, August 21st. Brookline Capital Markets began coverage on Revolution Medicines in a report on Monday, September 28th. They issued a “buy” rating and a $318.00 price objective for the company. Evercore reissued an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. Finally, William Blair assumed coverage on shares of Revolution Medicines in a report on Friday, October 16th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $242.90.

Insider Buying and Selling at Revolution Medicines

In other news, insider Stephen Kelsey sold 92,531 shares of Revolution Medicines stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the completion of the transaction, the insider directly owned 291,876 shares in the company, valued at approximately $59,064,027.36. This trade represents a 24.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lorence Kim sold 56,000 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $203.24, for a total value of $11,381,440.00. Following the completion of the sale, the director directly owned 17,090 shares in the company, valued at approximately $3,473,371.60. This represents a 76.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 290,991 shares of company stock valued at $59,422,765. 7.60% of the stock is currently owned by company insiders.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.